Lumos Pharma — NewLink Genetics — Q2 2018 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Jul 31, 2018
Slide 1: Second Quarter 2018 Financial Results
Second Quarter 2018 Financial Results NewLink Genetics Corporation Nasdaq: NLNK July 31, 2018
Slide 2: Agenda
Agenda Introduction • Lisa Miller, Director of Investor Relations Clinical Priorities and Organizational Realignment • Charles J. Link, Jr, MD, Chairman, CEO & CSO Clinical Updates and Guidance on Timing of Data • Eugene Kennedy, MD, Chief Medical Officer • Nicholas Vahanian, MD, President Comments
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward- looking statements,
Slide 4: Clinical Priorities
Clinical Priorities . Front-line diffuse intrinsic pontine glioma (DIPG) – Indoximod plus radio-chemotherapy for pediatric patients with DIPG – Early data show all patients demonstrated initial symptomatic improvement on therapy – Phase 1b trial ongoing with updated data anticipated 1H 2019 . Recurr
Slide 5: Corporate Reorganization
Corporate Reorganization . Jack Henneman appointed Chief Administrative Officer – To retire from NewLink Genetics November 2018 . Carl Langren promoted to Chief Financial Officer – Has served as Vice President of Finance . Brad Powers promoted to General Counsel – Has served as Associate General Cou
Slide 6: Encouraging Updated DIPG Data Presented at ISPNO
Encouraging Updated DIPG Data Presented at ISPNO Reported Results for 10 DIPG Patients (ISPNO July 2, 2018) • 9/10 remain on study • Longest treated 8.5 months at the time of the report • 10/10 experienced initial improvement in symptoms 6
Slide 7: Indoximod plus Chemotherapy in Acute Myeloid Leukemia (AML)
Indoximod plus Chemotherapy in Acute Myeloid Leukemia (AML) Phase 1b Exploring Minimal Residual Disease as a Surrogate Endpoint . Phase 1b trial for patients with newly diagnosed AML – Combination with current standard of care (7+3 chemotherapy) – Currently enrolling Phase 1b expansion cohort – Mini
Slide 8: Financial Position
Financial Position Q2 2018 End Cash and Equivalents $137.1 Million Quarterly Cash Use Projected ~$10 Million Cash Runway Projected ~3 Years Shares Outstanding as of June 30, 2018 37.2 Million 8
Slide 9: Key Takeaways
Key Takeaways Indoximod, an Immuno-oncology Candidate with Differentiated MOA . Clinical development plan for the most promising programs . Indoximod plus radio-chemotherapy in refractory or recurrent pediatric brain tumors . Indoximod plus radio-chemotherapy in front-line DIPG . Indoximod plus stan
Slide 10: Q & A
Q & A 10